Abbott has announced that data from a new study has shown that two blood-based biomarkers measured using its tests were able to predict a patient’s recovery from traumatic brain injury (TBI).
The company stated that testing for these two biomarkers immediately after an injury can help doctors determine the best treatments and care for patients.
In the study, published in The Lancet Neurology, Abbott’s i-STAT TBI Plasma test and its ARCHITECT core laboratory instrument were used to measure the two biomarkers in a blood sample.
